HUTCHMED (CHINA) LIMITED

Analyst Reco. HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:26 2024-04-18 am EDT			5-day change	1st Jan Change
271 ^GBX	+0.37%		-7.51%	-4.24%

Apr. 05	Hutchmed to Present New Data at US Cancer Research Conference	MT
Apr. 05	HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Upgrades HUTCHMED to Buy From Hold, Adjusts Price Target to $22.10 From $20	Nov. 24	MT
Goldman Sachs Adjusts Price Target on HUTCHMED (China) to $17 From $15, Maintains Neutral Rating	Nov. 10	MT
Hutchmed Says Platelet Disorder Drug Increased Durable Response Rate in Phase 3 Trial	23-08-21	MT
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating	22-08-09	MT
AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate	22-08-08	MT
AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Trial	22-08-08	MT
Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Shows Improved Response Rates	22-07-13	MT
Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $37	22-05-05	MT
HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy	21-09-22	MT
HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price Target	21-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer